PUBLICAÇÕES

@article{RodriguesToledo2024,

title = {EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics},

author = {Cibele Rodrigues Toledo and Ahmed A. Tantawy and Leonardo Lima Fuscaldi and Luciana Malavolta and Carolina de Aguiar Ferreira},

doi = {10.3390/ijms25158553},

issn = {1422-0067},

year  = {2024},

date = {2024-08-00},

urldate = {2024-08-00},

journal = {IJMS},

volume = {25},

number = {15},

publisher = {MDPI AG},

abstract = {<jats:p>The burgeoning field of cancer theranostics has witnessed advancements through the development of targeted molecular agents, particularly peptides. These agents exploit the overexpression or mutations of specific receptors, such as the Epidermal Growth Factor receptor (EGFR) and αVβ3 integrin, which are pivotal in tumor growth, angiogenesis, and metastasis. Despite the extensive research into and promising outcomes associated with antibody-based therapies, peptides offer a compelling alternative due to their smaller size, ease of modification, and rapid bioavailability, factors which potentially enhance tumor penetration and reduce systemic toxicity. However, the application of peptides in clinical settings has challenges. Their lower binding affinity and rapid clearance from the bloodstream compared to antibodies often limit their therapeutic efficacy and diagnostic accuracy. This overview sets the stage for a comprehensive review of the current research landscape as it relates to EGFR- and integrin αVβ3-targeting peptides. We aim to delve into their synthesis, radiolabeling techniques, and preclinical and clinical evaluations, highlighting their potential and limitations in cancer theranostics. This review not only synthesizes the extant literature to outline the advancements in peptide-based agents targeting EGFR and integrin αVβ3 but also identifies critical gaps that could inform future research directions. By addressing these gaps, we contribute to the broader discourse on enhancing the diagnostic precision and therapeutic outcomes of cancer treatments.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Candido2024,

title = {Crystal Structure and Anti-Proliferative and Mutagenic Evaluation of the Palladium(II) Complex of Deoxyalliin},

author = {Tuany Zambroti Candido and Mariana Mazzo Quintanilha and Bianca Alves Schimitd and Déborah de Alencar Simoni and Douglas Hideki Nakahata and Raphael Enoque Ferraz de Paiva and Igor Henrique Cerqueira and Flávia Aparecida Resende and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Carmen Silvia Passos Lima and Pedro Paulo Corbi},

doi = {10.3390/inorganics12070194},

issn = {2304-6740},

year  = {2024},

date = {2024-07-00},

urldate = {2024-07-00},

journal = {Inorganics},

volume = {12},

number = {7},

publisher = {MDPI AG},

abstract = {<jats:p>Platinum(II) and palladium(II) complexes have been investigated as potential anticancer drugs since the serendipitous discovery of the antineoplastic activities of cisplatin in the 1960s. Skin cancer is considered the most common malignant neoplasm that affects humans, and melanoma is the most lethal type of skin cancer. Surgical excision is the main form of treatment, which also may include radiotherapy, systemic chemotherapy, and immunotherapy. In this work, new insights concerning the structural characterization and in vitro anti-proliferative activity of the palladium(II) complex with the amino acid deoxyalliin (Pd-sac) against a panel of thirteen human tumor cells, with emphasis on skin cancer cell lines, are presented. The composition of the complex was confirmed by elemental analysis as [Pd(C6H10NO2S)2]. The structure of the complex was elucidated for the first time by a single-crystal X-ray diffraction technique. Each deoxyalliin molecule coordinates in a bidentate N,S-mode to palladium(II) in a trans-configuration analogous to the platinum(II) deoxyalliin complex early reported. As the main result, the Pd-sac complex showed a selective anti-proliferative activity against melanoma (UACC-62, TGI = 63.5 µM), while both deoxyalliin and K2PdCl4 were inactive against all cell lines. Moreover, Pd-sac did not affect the proliferation of non-tumorigenic keratinocytes (HaCaT, TGI > 586 µM) and was non-mutagenic in the Ames assay. The results open new perspectives for in vivo studies concerning the application of the Pd-sac complex in the treatment of melanoma.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Teixeira2024,

title = {New binuclear copper(I) complexes with dual bioactivity: Synthesis, structural characterization and biological assays against bacteria and cancer},

author = {Cristiane F.A. Teixeira and Estefane I. Teixeira and J.P.C. Nascimento and Amilcar M. Júnior and L.M.C. Pinto and Anderson R.L. Caires and G.B. Alcantara and Ana C. Micheletti and Victor M. Deflon and Davi F. Back and Heveline Silva and Lucas Pizzuti and Gleison Antônio Casagrande},

doi = {10.1016/j.ica.2023.121818},

issn = {0020-1693},

year  = {2024},

date = {2024-01-00},

urldate = {2024-01-00},

journal = {Inorganica Chimica Acta},

volume = {560},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Leitao2023,

title = {Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis},

author = {Renan C.F. Leitao and Francisco Silva and Gabriel H. Ribeiro and Isabel C. Santos and Joana F. Guerreiro and Filipa Mendes and Alzir A. Batista and Fernando R. Pavan and Pedro Ivo da S. Maia and António Paulo and Victor M. Deflon},

doi = {10.1016/j.jinorgbio.2022.112091},

issn = {0162-0134},

year  = {2023},

date = {2023-03-00},

urldate = {2023-03-00},

journal = {Journal of Inorganic Biochemistry},

volume = {240},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid39366100,

title = {Antibacterial profile and antiproliferative activities over human tumor cells of new silver(I) complexes containing two distinct trifluoromethyl uracil isomers},

author = {Gabriele de Menezes Pereira and Julia H Bormio Nunes and Vinicius Souza Macedo and Douglas Henrique Pereira and Kaio Eduardo Buglio and Daniele D Affonso and Ana Lucia T G Ruiz and João Ernesto de Carvalho and Silmara Cristina L Frajácomo and Wilton R Lustri and Carmen Silvia Passos Lima and Fernando R G Bergamini and Alexandre Cuin and Norberto Masciocchi and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2024.112752},

issn = {1873-3344},

year  = {2024},

date = {2024-10-01},

urldate = {2024-10-01},

journal = {J Inorg Biochem},

volume = {262},

pages = {112752},

abstract = {New silver(I) complexes of 5-(trifluoromethyl)uracil (5TFMU) and 6-(trifluoromethyl)uracil (6TFMU) isomers were synthesized, characterized, and evaluated as antibacterial and antiproliferative agents. Based on elemental and thermogravimetric analyses, the Ag-5TFMU and Ag-6TFMU species are formulated as AgCHFNO and AgCHFNO, respectively. Infrared and C solid-state nuclear magnetic resonance spectroscopies suggest coordination of the trifluoromethyluracil isomers to silver by both nitrogen and oxygen atoms. Confirmation of their structure and connectivity was achieved, in the absence of single crystals of suitable quality, by state-of-the-art structural powder diffraction methods. In Ag-5TFMU, the organic ligand is tridentate and two distinct metal coordination environments are found (linear AgN as well as C AgO geometries), whereas Ag-6TFMU contains a complex polymeric structure with tetradentate dianionic 6TFMU moieties and five distinct AgX (X = N, O) fragments, further stabilized by ancillary (longer) AgO contacts. These species presented modest activity over Gram-positive and Gram-negative bacterial strains, whereas Ag-6TFMU was active over a set of tumor cells, with the best activity over prostate (PC-3) and kidney cell lines and selectivity indices of 4.6 and 1.3, respectively. On the other hand, Ag-5TFMU was active over all considered tumor cells except MCF-7 (breast cancer). The best activity was found for PC-3 cells, but no selectivity was observed. The Ag-5TFMU and Ag-6TFMU species also reduced the proliferation of tongue squamous cell carcinoma cell lines SCC - 4 and SCC-15. Preliminary biophysical assays by circular dichroism suggest that the Ag-5TFMU complex interacts with DNA by intercalation, an effect not seen in Ag-6TFMU.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024,

title = {ASSESSMENT OF IN VITRO INTERACTIONS BETWEEN RADIOLABELED EGFR-TARGETING PEPTIDE INHIBITORS AND GLIOBLASTOMA CELLS},

author = {Fernanda Ferreira Mendonça and Alice Santos de Miranda and Henrique Massao Achidate Makino and Lorena Marinelli Mendes and Danielle Vieira Sobral and Marycel Figols de Barboza and Luciana Malavolta and Leonardo Lima Fuscaldi},

doi = {10.1016/j.htct.2024.04.065},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S10--S11},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rodrigues2024,

title = {ASSESSMENT OF IN VITRO STUDIES OF [131I]I-LABELED DEDEYFELV PEPTIDE AS PROSPECTIVE BIOMARKER FOR GLIOBLASTOMA},

author = {Fernanda Paiva Augusto Rodrigues and Júlia Calviello Giordano and Danielle Vieira Sobral and Ana Cláudia Camargo Miranda and Leonardo Lima Fuscaldi and Marycel Figols de Barboza and João Luiz Vitorino Araújo and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.063},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S9--S10},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Affonso2024,

title = {EVALUATION IN VITRO OF THE GOLD(I) COMPLEX WITH TRIPHENYLPHOSPHINE AND 4-DIMETHYLAAMINEPYRIDINE AS LIGANDS IN SKIN CANCER},

author = {Daniele Daiane Affonso and Tuany Zambroti Candido and João Ernesto de Carvalho and Pedro Paulo Corbi and Camilla Abbehausen and Ana Lucia Tasca Gois Ruiz and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.083},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S21--S22},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendes2024,

title = {EVALUATION OF POTENTIAL PEPTIDE INHIBITORS THAT INTERACT WITH THE EGF RECEPTOR. RELEVANCE TO GLIOBLASTOMA},

author = {Lorena Marinelli Mendes and Danielle Vieira Sobral and Érica Victória dos Santos and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.061},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024b,

title = {INVESTIGATION OF THE IN VITRO ASSESSMENT OF 99MTC-LABELED LAMININ-111 PEPTIDES AS PROSPECTIVE BIOMARKERS FOR BREAST CANCER},

author = {Fernanda Ferreira Mendonça and Maria Emilia Tejeria Perez and Paula Decuadra and Maia Zeni and Ana Rey and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.062},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S8--S9},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carron2024,

title = {INFLUENCE OF A CONVENTIONAL CHELATOR-MODIFIED ANTI-INTEGRIN PEPTIDE ON PROLIFERATION AND MIGRATION OF HEAD AND NECK CANCER CELLS},

author = {Juliana Carron and Daniele Daiane Affonso and Suelen Aparecida Ribeiro Souza and Ana Maria Castro Ferreira and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Gabriella Fraiji Melo and Flávio Lopes Alves and Leonardo Lima Fuscaldi and Luciana Malavolta and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.081},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Lima2024,

title = {PRELIMINARY ANTI-PROLIFERATIVE ACTIVITIES OF A PALLADIUM(II) COMPLEX OVER SQUAMOUS CELL CARCINOMA OF TONGUE},

author = {Carmen Silvia Passos Lima and Tuany Zambroti Candido and João Ernesto de Carvalho and Ana Lucia Tasca Gois Ruiz and Pedro Paulo Corbi},

doi = {10.1016/j.htct.2024.04.075},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S16--S17},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024c,

title = {SYNTHESIS AND EVALUATION OF BIOACTIVE PEPTIDES FROM LAMININ-111 IN TRIPLE-NEGATIVE BREAST CANCER CELLS},

author = {Fernanda Ferreira Mendonça and Júlia Torquato Vieira and Danielle Vieira Sobral and Érica Victória dos Santos and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.064},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fuscaldi2023,

title = {Radiochemical and biological assessments of a PSMA-I&S cold kit for fast and inexpensive 99mTc-labeling for SPECT imaging and radioguided surgery in prostate cancer},

author = {Leonardo Lima Fuscaldi and Danielle Vieira Sobral and Ana Claudia Ranucci Durante and Fernanda Ferreira Mendonça and Ana Cláudia Camargo Miranda and Carla Salgueiro and Silvia Gomez de Castiglia and Lilian Yuri Itaya Yamaga and Marcelo Livorsi da Cunha and Luciana Malavolta and Marycel Figols de Barboza and Jorge Mejia},

doi = {10.3389/fchem.2023.1271176},

issn = {2296-2646},

year  = {2023},

date = {2023-10-12},

urldate = {2023-10-12},

journal = {Front. Chem.},

volume = {11},

publisher = {Frontiers Media SA},

abstract = {<jats:p>The expression of prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer (PCa) cells and PSMA-ligands have been radiolabeled and used as radiopharmaceuticals for targeted radionuclide therapy (TRT), single photon emission computed tomography (SPECT) or positron emission tomography (PET) molecular imaging, and radioguided surgery in PCa patients. Herein, we aimed at radiolabeling the PSMA-I&S cold kit with <jats:sup>99m</jats:sup>Tc, resulting in a radiopharmaceutical with high radiochemical yield (RCY) and stability for SPECT imaging and radioguided surgery in PCa malignancies. Various pre-clinical assays were conducted to evaluate the [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S obtained by the cold kit. These assays included assessments of RCY, radiochemical stability in saline, lipophilicity, serum protein binding (SPB), affinity for LNCaP-PCa cells (binding and internalization studies), and <jats:italic>ex vivo</jats:italic> biodistribution profile in naive and LNCaP-PCa-bearing mice. The radiopharmaceutical was obtained with good RCY (92.05% ± 2.20%) and remained stable for 6 h. The lipophilicity was determined to be −2.41 ± 0.06, while the SPB was ∼97%. The binding percentages to LNCaP cells were 9.41% ± 0.57% (1 h) and 10.45% ± 0.45% (4 h), with 63.12 ± 0.93 (1 h) and 65.72% ± 1.28% (4 h) of the bound material being internalized. Blocking assays, employing an excess of unlabeled PSMA-I&S, resulted in a reduction in the binding percentage by 2.6 times. The <jats:italic>ex vivo</jats:italic> biodistribution profile confirmed high accumulation of [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S in the tumor and the tumor-to-contralateral muscle ratio was ∼6.5. In conclusion, [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S was successfully obtained by radiolabeling the cold kit using freshly eluted [<jats:sup>99m</jats:sup>Tc]NaTcO<jats:sub>4</jats:sub>, exhibiting good RCY and radiochemical stability. The preclinical assays demonstrated that the radiopharmaceutical shows favorable characteristics for SPECT imaging and radioguided surgery in PCa patients.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Bergamini2022,

title = {Investigating the antiproliferative activities of new CuII complexes with pyridine hydrazone derivatives of nalidixic acid},

author = {Fernando R.G. Bergamini and Julia H.B. Nunes and Carlos Marrote Manzano and Marcos Alberto de Carvalho and Marcos Antônio Ribeiro and Ana Lucia Tasca Gois Ruiz and João Ernesto de Carvalho and Wilton Rogério Lustri and Raphael Enoque Ferraz de Paiva and Marcelo Cecconi Portes and Ana Maria da Costa Ferreira and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2022.111881},

issn = {0162-0134},

year  = {2022},

date = {2022-09-00},

urldate = {2022-09-00},

journal = {Journal of Inorganic Biochemistry},

volume = {234},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Candido2022,

title = {Silver Nimesulide Complex in Bacterial Cellulose Membranes as an Innovative Therapeutic Method for Topical Treatment of Skin Squamous Cell Carcinoma},

author = {Tuany Zambroti Candido and Raphael Enoque Ferraz de Paiva and Mariana Cecchetto Figueiredo and Lilian de Oliveira Coser and Silmara Cristina Lazarini Frajácomo and Camilla Abbehausen and Izilda Aparecida Cardinalli and Wilton Rogerio Lustri and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Pedro Paulo Corbi and Carmen Silvia Passos Lima},

doi = {10.3390/pharmaceutics14020462},

issn = {1999-4923},

year  = {2022},

date = {2022-02-00},

urldate = {2022-02-00},

journal = {Pharmaceutics},

volume = {14},

number = {2},

publisher = {MDPI AG},

abstract = {<jats:p>Oxidative stress and inflammation act on skin squamous cell carcinoma (SSCC) development and progression. Curative therapy for SSCC patients is mainly based on surgical resection, which can cause various sequelae. Silver ions have in vitro activities over tumor cells, while nimesulide has antioxidant and anti-inflammatory activities. This study aimed to evaluate the effects of a silver(I) complex with nimesulide (AgNMS) incorporated in a sustained release device based on bacterial cellulose membrane, named AgNMS@BCM, on topic SSCC treatment. The antiproliferative effect of AgNMS complex was evaluated in the SCC4, SCC15 and FaDu SCC lines. AgNMS complex activity on exposure of phosphatidylserine (PS) residues and multicaspase activation were evaluated on FaDu cells by flow cytometry. The AgNMS@BCM effects were evaluated in a SSCC model induced by 7,12-dimethylbenzanthracene/12-o-tetradecanoyl-phorbol-13-acetate (DMBA/TPA) in mice. Toxicity and tumor size were evaluated throughout the study. AgNMS complex showed antiproliferative activity in SCC15 and FaDu lines in low to moderate concentrations (67.3 µM and 107.3 µM, respectively), and induced multicaspase activation on FaDu cells. The AgNMS@BCM did not induce toxicity and reduced tumor size up to 100%. Thus, the application of AgNMS@BCM was effective and safe in SSCC treatment in mice, and can be seen as a potential and safe agent for topic treatment of SSCC in humans.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sobral2022,

title = {Comparative Evaluation of Radiochemical and Biological Properties of 131I- and [99mTc]Tc(CO)3-Labeled RGD Analogues Planned to Interact with the αvβ3 Integrin Expressed in Glioblastoma},

author = {Danielle V. Sobral and Leonardo L. Fuscaldi and Ana Claudia R. Durante and Fernanda F. Mendonça and Larissa R. de Oliveira and Ana Cláudia C. Miranda and Jorge Mejia and Wagner R. Montor and Marycel F. de Barboza and Luciana Malavolta},

doi = {10.3390/ph15020116},

issn = {1424-8247},

year  = {2022},

date = {2022-02-00},

urldate = {2022-02-00},

journal = {Pharmaceuticals},

volume = {15},

number = {2},

publisher = {MDPI AG},

abstract = {<jats:p>Radiolabeled peptides with high specificity for overexpressed receptors in tumor cells hold great promise for diagnostic and therapeutic applications. In this work, we aimed at comparing the radiolabeling efficiency and biological properties of two different RGD analogs: GRGDYV and GRGDHV, labeled with iodine-131 (131I) and technetium-99m-tricarbonyl complex [99mTc][Tc(CO)3]+. Additionally, we evaluated their interaction with the αvβ3 integrin molecule, overexpressed in a wide variety of tumors, including glioblastoma. Both peptides were chemically synthesized, purified and radiolabeled with 131I and [99mTc][Tc(CO)3]+ using the chloramine-T and tricarbonyl methodologies, respectively. The stability, binding to serum proteins and partition coefficient were evaluated for both radioconjugates. In addition, the binding and internalization of radiopeptides to rat C6 glioblastoma cells and rat brain homogenates from normal animals and a glioblastoma-induced model were assessed. Finally, ex vivo biodistribution studies were carried out. Radiochemical yields between 95–98% were reached for both peptides under optimized radiolabeling conditions. Both peptides were stable for up to 24 h in saline solution and in human serum. In addition, the radiopeptides have hydrophilic characteristics and a percentage of binding to serum proteins around 35% and 50% for the [131I]I-GRGDYV and [99mTc]Tc(CO)3-GRGDHV fragments, respectively. Radiopeptides showed the capacity of binding and internalization both in cell culture (C6) and rat brain homogenates. Biodistribution studies corroborated the results obtained with brain homogenates and confirmed the different binding characteristics due to the exchange of radionuclides and the presence of the tricarbonyl complex. Thereby, the results showed that both radiopeptides might be considered for future clinical applications.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fuscaldi2021,

title = {Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer},

author = {Leonardo L. Fuscaldi and Danielle V. Sobral and Ana Claudia R. Durante and Fernanda F. Mendonça and Ana Cláudia C. Miranda and Marcelo L. da Cunha and Luciana Malavolta and Jorge Mejia and Marycel F. de Barboza},

doi = {10.3390/ph14050385},

issn = {1424-8247},

year  = {2021},

date = {2021-05-00},

urldate = {2021-05-00},

journal = {Pharmaceuticals},

volume = {14},

number = {5},

publisher = {MDPI AG},

abstract = {<jats:p>Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging techniques. The aim of the present work was to standardize and validate an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11, as well as to produce a radiopharmaceutical for PET imaging of PCa malignancies. [68Ga]Ga-PSMA-11 was evaluated to determine the radiochemical purity (RCP), stability in saline solution and serum, lipophilicity, affinity to serum proteins, binding and internalization to lymph node carcinoma of the prostate (LNCaP) cells, and ex vivo biodistribution in mice. The radiopharmaceutical was produced with an RCP of 99.06 ± 0.10%, which was assessed with reversed-phase high-performance liquid chromatography (RP-HPLC). The product was stable in saline solution for up to 4 h (RCP > 98%) and in serum for up to 1 h (RCP > 95%). The lipophilicity was determined as −3.80 ± 0.15, while the serum protein binding (SPB) was <17%. The percentages of binding to LNCaP cells were 4.07 ± 0.51% (30 min) and 4.56 ± 0.46% (60 min), while 19.22 ± 2.73% (30 min) and 16.85 ± 1.34% (60 min) of bound material was internalized. High accumulation of [68Ga]Ga-PSMA-11 was observed in the kidneys, spleen, and tumor, with a tumor-to-contralateral-muscle ratio of >8.5 and a tumor-to-blood ratio of >3.5. In conclusion, an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11 was standardized and the product was evaluated, thus verifying its characteristics for PET imaging of PCa tumors in a clinical environment.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sobral2020,

title = {Radiochemical and biological properties of peptides designed to interact with EGF receptor: Relevance for glioblastoma},

author = {Danielle V. Sobral and Leonardo L. Fuscaldi and Ana Claudia R. Durante and Mayara G. Rangel and Larissa R. Oliveira and Fernanda F. Mendonça and Ana Cláudia C. Miranda and Jorge M. Cabeza and Wagner R. Montor and Francisco R. Cabral and Marycel F.F. Barboza and Luciana Malavolta},

doi = {10.1016/j.nucmedbio.2020.07.001},

issn = {0969-8051},

year  = {2020},

date = {2020-09-00},

urldate = {2020-09-00},

journal = {Nuclear Medicine and Biology},

volume = {88-89},

pages = {14--23},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{BormioNunes2019,

title = {New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells},

author = {Julia H. Bormio Nunes and Paula P. de Paiva and Ana Lúcia T.G. Ruiz and João Ernesto de Carvalho and Pedro P. Corbi},

doi = {10.1016/j.tiv.2019.06.018},

issn = {0887-2333},

year  = {2019},

date = {2019-10-00},

urldate = {2019-10-00},

journal = {Toxicology in Vitro},

volume = {60},

pages = {359--368},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Almeida2024,

title = {Radioligand Therapy in Lymphoma},

author = {Ludmila Santiago Almeida and Roberto C. Delgado Bolton and Victor Cabral Heringer and Samuel de Souza Medina and Elba Etchebehere},

doi = {10.1016/j.cpet.2024.05.003},

issn = {1556-8598},

year  = {2024},

date = {2024-07-00},

urldate = {2024-07-00},

journal = {PET Clinics},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024,

title = {177LU-PSMA IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER: PRELIMINARY ANALYSIS OF A BRAZILIAN MULTICENTRIC STUDY},

author = {Victor Cabral Costa Ribeiro Heringer and Felipe P.G. Ribeiro and Diogo Bastos and Camila Mosci and Dalton A. Anjos and Paulo Almeida Filho and Gustavo Gomes and Filipe Villela-Pedras and Fabio Ribeiro and Julio Correia and José F. Marin and Carlos Buchpiguel and Elba C.S.C. Etchebehere},

doi = {10.1016/j.htct.2024.04.071},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{doNascimento2024,

title = {18F-FLUORIDE PET/CT vs 18F-PSMA-1007 TO DETECT BONE METASTASES IN PROSTATE CANCER – A HEAD-TO-HEAD PROSPECTIVE COMPARISON},

author = {Beatriz Birelli do Nascimento and Allan Santos and Natalia Tobar and Fabiana Mori and Mariana Camacho and Mariana Lima and Edna Brunetto and Sergio Brunetto and Anelise Ruzzarin and Juliana Ciampi and Marina Silveira and Gardenia Oliveira Barbosa and Wagner Matheus and Ubirajara Ferreira and Elba Etchebehere},

doi = {10.1016/j.htct.2024.04.088},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S24--S25},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024d,

title = {ARTIFICIAL INTELLIGENCE TO EVALUATE METABOLIC TUMOR BURDEN IN PRIMARY STAGING OF RECTAL CANCER WITH 18F-FDG PET/CT},

author = {Victor Cabral Costa Ribeiro Heringer and Maria Carolina S. Mendes and Barbara Juarez Amorim and Allan Oliveira Santos and Marina N. Silveira and Cleide Silva and Juliano S. Fonseca and Mariana C.L. Lima and Lorena P. Cunha and Carlos Augusto R. Martinez and Claudio Coy and Jose Barreto C. Carvalheira and Elba Cristina Sá de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.054},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S3--S4},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silveira2024,

title = {COMPARISON OF 18F-FDG AND 18F-PSMA PET/CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER},

author = {Najua Abou Arabi Silveira and Maurício Wesley Perroud Júnior and Hugo Nakano Ide and Kaique Moraes do Amaral and Simone Kuba and Natália Tobar and Thiago Ferreira de Souza and Carmen Silva Passos Lima and José Barreto Campello Carvalheira and Barbara Juarez Amorim and Elba Cristina Sá de Camargo Etchebehere and Mariana da Cunha Lopes de Lima and Allan de Oliveira Santos and Ludimila Santiago Almeida and Maria Emília Seren Takahashi and Eliana Cristina Martins Miranda and Carmino Antonio de Souza and Sérgio Querino Brunetto and Celso Dario Ramos},

doi = {10.1016/j.htct.2024.04.079},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sousa2024,

title = {COMPARISON OF 18 F-FDG AND 18 F-PSMA-1007 PET/CT IN ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMA OF HEAD AND NECK: PRELIMINARY RESULTS},

author = {Hadila Da Silva Veras Sousa and Kaique Moraes do Amaral and Najua Abou Arab and Simone Kuba and Lígia Traldi Macedo and Bárbara Juarez Amorim and Celso Dario Ramos and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.084},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S22--S23},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Tineo2024,

title = {COMPARISON BETWEEN PET/CT WITH 18F-PSMA-1007 AND WITH 18F-FDG IN MUSCLE-INVASIVE BLADDER UROTHELIAL CARCINOMA},

author = {Ricardo Norberto Tineo and Natalia Dalsenter Avilez and Juliano Tomé Rodrigues and Felipe Piccarone G Ribeiro and Helena Paes de Alm de Saito and Frederico Leal and Barbara Juazer Amorim and Jose Barrreto C. Carvalheira and Leonardo Oliveira Reis and Celso Dario Ramos},

doi = {10.1016/j.htct.2024.04.086},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S23--S24},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silva2024,

title = {COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN MUSCULOSKELETAL TUMORS TO EVALUATE THE POTENTIAL OF THERANOSTICS APPROACH},

author = {Mayara Branco E. Silva and Natalia Tobar and Allan de Oliveira Santos and Gardenia De Oliveira Barbosa and Carlos Eduardo Hideo Hanasilo and Mariana Da Cunha Lopes de Lima and Mauricio Etchebehere and Elba Cristina Sa de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.089},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S25--S26},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendanha2024,

title = {COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN METASTATIC ACRAL MELANOMA: A CASE REPORT},

author = {Diego Machado Mendanha and Natalia Tobar and Ligia Traldi Macedo and Allan Oliveira Santos and Mariana Cunha Lopes de Lima and Elba Cristina Sá de Camargo Etchebehere and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.102},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sousa2024b,

title = {COMPARISON OF PET/CT IMAGES WITH 18 F-FDG AND 18 F-PSMA-1007 IN RELAPSED ADENOID CYSTIC CARCINOMA},

author = {Hadila Da Silva Veras Sousa and Natália Tobar and Lígia Traldi Macedo and Simone Kuba and Allan de Oliveira Santos and Bárbara Juarez Amorim and Carmen Silvia Passos Lima and Elba Cristina Sá de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.082},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2024,

title = {COMPARISON OF IBI AND PBI CALCULATED FOR 68GA-PSMA AND 18F-FDG IN MULTIPLE MYELOMA PATIENTS},

author = {Maria Emilia Seren Takahashi and Stephan P.M. Souza and Fernanda C. Frasson and Gislaine B. Oliveira and Vania P. Castro and Fernando V. Pericole and Lício A. Velloso and Cármino A. Souza and Irene G.H. Lorand-Metze and Allan O. Santos and Celso Darío Ramos},

doi = {10.1016/j.htct.2024.04.087},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Reis2024,

title = {COMPARISON OF 68GA-PSMA AND 18F-FDG-PET/CT IN THE ASSESSMENT OF DESMOID TUMORS},

author = {Tobias Luis dos Reis and Kaique Moraes do Amaral and Najua Abou Arab and Maria Emilia Seren Takahashi and José Barreto Campello Carvalheira and Barbara Juarez Amorim and Elba Cristina Sá de Camargo Etchebehere and Mariana da Cunha Lopes de Lima and Allan de Oliveira Santos and Ludmila Santiago Almeida and Eliana Cristina Martins Miranda and Carmen Silvia Passos Lima and Celso Dario Ramos and Sérgio Querino Brunetto and Simone Kuba and NAtália Tobar and Carmino Antonio Souza and Mariana Cortês Caleffi and Mariana Fernandes França Mitre Amorim},

doi = {10.1016/j.htct.2024.04.080},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S19--S20},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Amaral2024,

title = {DUAL-TRACER PET/CT IN MYELOFIBROSIS: A CASE SERIES ANALYSIS USING 18F-FDG AND 18F-PSMA PET/CT},

author = {Kaique M. Amaral and Katia B.B. Pagnano and Victor Cabral Costa Ribeiro Heringer and Sergio Q. Brunetto and Simone Kuba and Maria Emilia S. Takahashi and Allan O. Santos and Barbara J. Amorim and Elba C.S.C. Etchebehere and Mariana C.L. Lima and Carmino A. Souza and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.109},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Liveraro2024,

title = {DEEP LEARNING FOR CT IMAGES SEGMENTATION},

author = {Gianni Shigeru Setoue Liveraro and Maria Emília Seren Takahashi and Fabiana Lascala and Maria Carolina Santos Mendes and Jun Takahashi and José Barreto Campello Carvalheira},

doi = {10.1016/j.htct.2024.04.058},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{HERINGER2024b,

title = {RADIOLIGAND THERAPY IN LYMPHOMA: PAST, PRESENT AND FUTURE},

author = {Victor C.C.R. HERINGER and Ludmila S. ALMEIDA and Roberto C. DELGADO BOLTON and Daniel C. PANCIEIRA and Samuel S MEDINA and Elba C.S.C. ETCHEBEHERE},

doi = {10.1016/j.htct.2024.04.115},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Amaral2024b,

title = {TREATMENT OF REFRACTORY MULTIPLE MYELOMA WITH PSMA-177LU: A CASE REPORT},

author = {Kaique M. Amaral and Felipe P.G. Ribeiro and Fernando V.P. Souza and Allan O. Santos and Sergio Q. Brunetto and Maria Emilia S. Takahashi and Vania P. Castro and Carmem S.P. Lima and Barbara J. Amorim and Carmino A. Souza and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.104},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{ETCHEBEHERE2024,

title = {THERANOSTICS: NUCLEAR MEDICINE IN PROSTATE CANCER},

author = {Marina Camargo ETCHEBEHERE and Helena da Cunha Lopes DE LIMA and Mariana da Cunha Lopes DE LIMA and Elba Cristina Sá de Camargo ETCHEBEHERE},

doi = {10.1016/j.htct.2024.04.111},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Siqueira2024,

title = {TRATAMENTO BEM-SUCEDIDO DE PACIENTE COM DIAGNÓSTICO DE VIPOMA METASTÁTICO COM TRATAMENTO TERANÓSTICO OCTREOTATO-DOTA-177 LUTÉCIO},

author = {Nadia Sclearuc de Siqueira and Helena Paes Almeida Saito and Felipe Osorio Costa and Everton Cazzo and Allan Oliveira Santos and Jose Barreto Campello Carvalheira},

doi = {10.1016/j.htct.2024.04.097},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024c,

title = {THE ROLE OF PET/CT IN DETECTING OCCULT DISEASE IN SYNCHRONOUS TUMORS: A CASE REPORT OF MERKEL CELL CARCINOMA AND NON-HODGKIN LYMPHOMA},

author = {Victor C.C.R. Heringer and Fabíola F. Zarpelão and Kaique M. Amaral and Nájua A.A. Silveira and Ricardo N. Tineo and Thais A. Tognoli and Dihego F. Santos and Felipe P.G. Ribeiro and Thiago F. Souza and Mariana Lima and Allan O. Santos and Barbara J. Amorim and Elba C.S.C. Etchebehere and Ludmila S. Almeida and Carmen S.P. Lima and Jose B.C. Carvalheira and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.100},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid38472569,

title = {Evidence of brain metabolism redistribution from neocortex to primitive brain structures in early acute COVID-19 respiratory syndrome},

author = {Stephan P M Souza and Nicoli Colet and Mariana Fujiwara and Alins P Fernandes and Natalia Tobar and Sergio S J Dertkigil and Maria Emilia S Takahashi and Bárbara J Amorim and Lucas S Silva and Clarissa L Yasuda and Fernando Cendes and Thiago F de Souza and Juliano T Rodrigues and Denise E Zantut-Wittmann and Celso Dario Ramos},

doi = {10.1186/s13550-024-01089-3},

issn = {2191-219X},

year  = {2024},

date = {2024-03-01},

urldate = {2024-03-01},

journal = {EJNMMI Res},

volume = {14},

number = {1},

pages = {28},

abstract = {BACKGROUND: Neuropsychiatric sequelae of COVID-19 have been widely documented in patients with severe neurological symptoms during the chronic or subacute phase of the disease. However, it remains unclear whether subclinical changes in brain metabolism can occur early in the acute phase of the disease. The aim of this study was to identify and quantify changes in brain metabolism in patients hospitalized for acute respiratory syndrome due to COVID-19 with no or mild neurological symptoms.nnRESULTS: Twenty-three non-intubated patients (13 women; mean age 55.5 ± 12.1 years) hospitalized with positive nasopharyngeal swab test (RT-PCR) for COVID-19, requiring supplemental oxygen and no or mild neurological symptoms were studied. Serum C-reactive protein measured at admission ranged from 6.43 to 189.0 mg/L (mean: 96.9 ± 54.2 mg/L). The mean supplemental oxygen demand was 2.9 ± 1.4 L/min. [F]FDG PET/CT images were acquired with a median of 12 (4-20) days of symptoms. After visual interpretation of the images, semiquantitative analysis of [F]FDG uptake in multiple brain regions was evaluated using dedicated software and the standard deviation (SD) of brain uptake in each region was automatically calculated in comparison with reference values of a normal database. Evolutionarily ancient structures showed positive SD mean values of [F]FDG uptake. Lenticular nuclei were bilaterally hypermetabolic (> 2 SD) in 21/23 (91.3%) patients, and thalamus in 16/23 (69.6%), bilaterally in 11/23 (47.8%). About half of patients showed hypermetabolism in brainstems, 40% in hippocampi, and 30% in cerebellums. In contrast, neocortical regions (frontal, parietal, temporal and occipital lobes) presented negative SD mean values of [F]FDG uptake and hypometabolism (< 2 SD) was observed in up to a third of patients. Associations were found between hypoxia, inflammation, coagulation markers, and [F]FDG uptake in various brain structures.nnCONCLUSIONS: Brain metabolism is clearly affected during the acute phase of COVID-19 respiratory syndrome in neurologically asymptomatic or oligosymptomatic patients. The most frequent finding is marked hypermetabolism in evolutionary ancient structures such as lenticular nucleus and thalami. Neocortical metabolism was reduced in up to one third of patients, suggesting a redistribution of brain metabolism from the neocortex to evolutionary ancient brain structures in these patients.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Souza2023,

title = {Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma},

author = {Stephan P. M. Souza and Fernanda C. Frasson and Maria Emilia S. Takahashi and Gislaine B. O. Duarte and Vania P. Castro and Fernando V. Pericole and Licio A. Velloso and Carmino A. De Souza and Irene Lorand-Metze and Allan O. Santos and Celso D. Ramos},

doi = {10.1007/s00259-023-06214-3},

issn = {1619-7089},

year  = {2023},

date = {2023-07-00},

urldate = {2023-07-00},

journal = {Eur J Nucl Med Mol Imaging},

volume = {50},

number = {8},

pages = {2432--2440},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36656866,

title = {Metformin acts in the gut and induces gut-liver crosstalk},

author = {Natália Tobar and Guilherme Z Rocha and Andrey Santos and Dioze Guadagnini and Heloísa B Assalin and Juliana A Camargo and Any E S S Gonçalves and Flavia R Pallis and Alexandre G Oliveira and Silvana A Rocco and Raphael M Neto and Irene Layane de Sousa and Marcos R Alborghetti and Maurício L Sforça and Patrícia B Rodrigues and Raissa G Ludwig and Emerielle C Vanzela and Sergio Q Brunetto and Patrícia A Boer and José A R Gontijo and Bruno Geloneze and Carla R O Carvalho and Patricia O Prada and Franco Folli and Rui Curi and Marcelo A Mori and Marco A R Vinolo and Celso D Ramos and Kleber G Franchini and Claudio F Tormena and Mario J A Saad},

doi = {10.1073/pnas.2211933120},

issn = {1091-6490},

year  = {2023},

date = {2023-01-01},

urldate = {2023-01-01},

journal = {Proc Natl Acad Sci U S A},

volume = {120},

number = {4},

pages = {e2211933120},

abstract = {Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2022,

title = {Beyond the \textit{AJR}: The Rapid Clinical Acceptance of PSMA PET Causes Important Bias in Open-Label Trials},

author = {Celso Dario Ramos},

doi = {10.2214/ajr.21.27241},

issn = {1546-3141},

year  = {2022},

date = {2022-08-00},

urldate = {2022-08-00},

journal = {American Journal of Roentgenology},

volume = {219},

number = {2},

pages = {349--349},

publisher = {American Roentgen Ray Society},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deSouzaSantos2022,

title = {18F-FDG PET/CT in Late Acquisition Identifies Sites of Active Disease in Treated Takayasu Arteritis},

author = {Marília Paula de Souza Santos and Celso Dario Ramos and Mariana Paixão and Estephania Pignaton Naseri and Manoel Barros Bertolo and Zoraida Sachetto},

doi = {10.1097/rhu.0000000000001801},

issn = {1536-7355},

year  = {2022},

date = {2022-00-00},

urldate = {2022-00-00},

journal = {J Clin Rheumatol},

volume = {28},

number = {1},

pages = {14--20},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Objective</jats:title>

            <jats:p>Few studies have taken advantage of <jats:sup>18</jats:sup>F-fluorodeoxyglucose positron emission tomography associated with computed tomography (<jats:sup>18</jats:sup>F-FDG PET/CT) to personalize patient evaluation and identify sites of more active disease in Takayasu arteritis (TA)–treated patients. This study aimed to evaluate the utility of <jats:sup>18</jats:sup>F-FDG PET/CT in late acquisition in identifying sites of active disease in patients under full treatment for TA.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>In this cross-sectional study, patients under full treatment underwent whole-body <jats:sup>18</jats:sup>F-FDG PET/CT. Sites of increased <jats:sup>18</jats:sup>F-FDG uptake were classified by a score of 3 on the visual scale using the liver uptake as reference. A quantitative analysis was also performed by measuring the maximum standardized uptake value (SUV) of the vascular wall of affected arteries. Disease activity using the National Institutes of Health criteria was also evaluated.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Of the 20 patients, there were 18 female and 2 male patients, with a mean age of 43.6 (±11.58) years and a disease duration of 8.3 (±6.25) years. Thirteen participants (65%) were in inflammatory activity according to the criteria proposed by the National Institutes of Health. All patients received immunosuppressive agents, and one of them received immunobiological treatment. The highest SUV value was 6.2 in the aortic arch, and the lowest was 1.0 in the subclavian artery. The mean maximum SUV did not differ between clinically active and inactive patients. In the visual analysis, all participants had at least 1 vascular site with inflammatory activity, with an uptake ≥2 in relation to the liver. The aortic arch was the most frequently involved site.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusions</jats:title>

            <jats:p>This study showed that <jats:sup>18</jats:sup>F-FDG PET/CT in late acquisition is an effective imaging method to assess TA activity even in fully treated patients.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2022b,

title = {Multimodality molecular imaging in arthropathy associated with multiple myeloma},

author = {CelsoDario Ramos and LudmilaSantiago Almeida and StephanPinheiro Macedo de Souza and FernandoVieira Pericole de Souza and Fabiano Reis},

doi = {10.4103/ijnm.ijnm_205_21},

issn = {0972-3919},

year  = {2022},

date = {2022-00-00},

urldate = {2022-00-00},

journal = {Indian J Nucl Med},

volume = {37},

number = {3},

publisher = {Medknow},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carraro2021,

title = {Arcuate Nucleus Overexpression of NHLH2 Reduces Body Mass and Attenuates Obesity-Associated Anxiety/Depression-like Behavior},

author = {Rodrigo S. Carraro and Guilherme A. Nogueira and Davi Sidarta-Oliveira and Rodrigo S. Gaspar and Nathalia R. Dragano and Joseane Morari and Vanessa C. D. Bobbo and Eliana P. Araujo and Natalia F. Mendes and Ariane M. Zanesco and Natalia Tobar and Celso D. Ramos and Jéssica M. Toscaro and Marcio C. Bajgelman and Licio A. Velloso},

doi = {10.1523/jneurosci.0222-21.2021},

issn = {1529-2401},

year  = {2021},

date = {2021-12-01},

urldate = {2021-12-01},

journal = {J. Neurosci.},

volume = {41},

number = {48},

pages = {10004--10022},

publisher = {Society for Neuroscience},

abstract = {<jats:p>Nescient helix-loop-helix 2 (NHLH2) is a hypothalamic transcription factor that controls the expression of prohormone convertase 1/3, therefore having an impact on the processing of proopiomelanocortin and thus on energy homeostasis. Studies have shown that KO of<jats:italic>Nhlh2</jats:italic>results in increased body mass, reduced physical activity, and hypogonadism. In humans, a polymorphism of the<jats:italic>NHLH2</jats:italic>gene is associated with obesity; and in Prader–Willi syndrome, a condition characterized by obesity, hypogonadism and behavioral abnormalities, the expression of NHLH2 is reduced. Despite clinical and experimental evidence suggesting that NHLH2 could be a good target for the treatment of obesity, no previous study has evaluated the impact of NHLH2 overexpression in obesity. Here, in mice fed a high-fat diet introduced right after the arcuate nucleus intracerebroventricular injection of a lentivirus that promoted 40% increase in NHLH2, there was prevention of the development of obesity by a mechanism dependent on the reduction of caloric intake. When hypothalamic overexpression of NHLH2 was induced in previously obese mice, the beneficial impact on obesity-associated phenotype was even greater; thus, there was an 80% attenuation in body mass gain, reduced whole-body adiposity, increased brown adipose tissue temperature, reduced hypothalamic inflammation, and reduced liver steatosis. In this setting, the beneficial impact of hypothalamic overexpression of NHLH2 was a result of combined effects on caloric intake, energy expenditure, and physical activity. Moreover, the hypothalamic overexpression of NHLH2 reduced obesity-associated anxiety/depression behavior. Thus, we provide an experimental proof of concept supporting that hypothalamic NHLH2 is a good target for the treatment of obesity.</jats:p><jats:p><jats:bold>SIGNIFICANCE STATEMENT</jats:bold>Obesity is a highly prevalent medical condition that lacks an effective treatment. The main advance provided by this study is the demonstration of the beneficial metabolic and behavioral outcomes resulting from the overexpression of NHLH2 in the hypothalamus. When NHLH2 was overexpressed simultaneously with the introduction of a high-fat diet, there was prevention of obesity by a mechanism dependent on reduced caloric intake. Conversely, when NHLH2 was overexpressed in previously obese mice, there was reduction of the obese phenotype because of a combination of reduced caloric intake, increased physical activity, and increased thermogenesis. In addition, the overexpression of NHLH2 reduced anxiety/depression-like behavior. Thus, NHLH2 emerges as a potential target for the combined treatment of obesity and its associated anxiety/depression-like behavior.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2021,

title = {Metabolic Volume Measurements in Multiple Myeloma},

author = {Maria Emilia Seren Takahashi and Irene Lorand-Metze and Carmino Antonio de Souza and Claudio Tinoco Mesquita and Fernando Amorim Fernandes and José Barreto Campello Carvalheira and Celso Dario Ramos},

doi = {10.3390/metabo11120875},

issn = {2218-1989},

year  = {2021},

date = {2021-12-00},

urldate = {2021-12-00},

journal = {Metabolites},

volume = {11},

number = {12},

publisher = {MDPI AG},

abstract = {<jats:p>Multiple myeloma (MM) accounts for 10–15% of all hematologic malignancies, as well as 20% of deaths related to hematologic malignant tumors, predominantly affecting bone and bone marrow. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose (FDG-PET/CT) is an important method to assess the tumor burden of these patients. It is often challenging to classify the extent of disease involvement in the PET scans for many of these patients because both focal and diffuse bone lesions may coexist, with varying degrees of FDG uptake. Different metrics involving volumetric parameters and texture features have been proposed to objectively assess these images. Here, we review some metabolic parameters that can be extracted from FDG-PET/CT images of MM patients, including technical aspects and predicting MM outcome impact. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are volumetric parameters known to be independent predictors of MM outcome. However, they have not been adopted in clinical practice due to the lack of measuring standards. CT-based segmentation allows automated, and therefore reproducible, calculation of bone metabolic metrics in patients with MM, such as maximum, mean and standard deviation of the standardized uptake values (SUV) for the entire skeleton. Intensity of bone involvement (IBI) is a new parameter that also takes advantage of this approach with promising results. Other indirect parameters obtained from FDG-PET/CT images, such as visceral adipose tissue glucose uptake and subcutaneous adipose tissue radiodensity, may also be useful to evaluate the prognosis of MM patients. Furthermore, the use and quantification of new radiotracers can address different metabolic aspects of MM and may have important prognostic implications.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2021,

title = {Fixed 30 mCi (1110 MBq) 131I-iodine therapy in autonomously functioning nodules: Single toxic nodule as a predictive factor of success},

author = {Lívia Pereira and Cinthia Riguetto and Arnaldo Neto and Marcos Tambascia and Celso Ramos and Denise Zantut-Wittmann},

doi = {10.4103/wjnm.wjnm_150_20},

issn = {1607-3312},

year  = {2021},

date = {2021-10-00},

urldate = {2021-10-00},

journal = {World J Nucl Med},

volume = {20},

number = {04},

pages = {349--354},

publisher = {Georg Thieme Verlag KG},

abstract = {<jats:title>Abstract</jats:title><jats:p>Aims: The aim of this study is to evaluate the efficacy of a fixed 30 mCi (1110 MBq) 131I-iodine dose for the treatment of hyperthyroidism due to uninodular or multinodular toxic goiter and identify predictors of success. Materials and Methods: Fifty-nine patients diagnosed with nonautoimmune toxic goiter were treated with a fixed 30 mCi dose of 131I-iodine and were followed at a tertiary service between 2000 and 2016. The therapy was considered successful if the patient reached euthyroidism or hypothyroidism without needing an extra 131I-iodine dose or antithyroid drugs for at least 1 year after the radioiodine therapy (RIT). Results: Patients with a single toxic nodule were younger at diagnosis (52 vs. 63 years; P = 0.007), presented a shorter disease duration until RIT (2 vs. 3.5 years; P = 0.007), smaller total thyroid volume (20 vs. 82 cm3; P = 0.044), and lower pre-RIT thyroid uptake (P = 0.043) than patients with multinodular goiter. No significant difference was seen with antithyroid drug use, thyroid-stimulating hormone and free thyroxine level, and follow-up after RIT. After RIT, 47 patients (79.66%) met the success criteria, and 12 (20.33%) remained hyperthyroid. Among the success group, 32 (68.08%) reached euthyroidism, while 31.92% developed hypothyroidism after 1 year. Patients with single toxic nodules who achieved success after RIT presented smaller nodules (2.8 vs. 5.75 cm; P = 0.043), while the pre-RIT thyroid uptake was higher among patients with multinodular toxic goiter who achieved success after RIT (5.5% vs. 1.5%; P = 0.007). A higher success rate was observed among patients with a single toxic nodule than those with a toxic multinodular goiter (92.3% vs. 55%; P = 0.001), and a single toxic nodule presentation was found to be an independent predictor of success (P = 0.009). Conclusions: The fixed 30 mCi 131I-iodine dose was particularly effective in the group of patients with single autonomously functioning nodule rather than the group with multiple nodules. A single toxic nodule was an independent predictor of treatment success.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deMoura2021,

title = {Docetaxel and Lidocaine Co-Loaded (NLC-in-Hydrogel) Hybrid System Designed for the Treatment of Melanoma},

author = {Ludmilla David de Moura and Lígia N. M. Ribeiro and Fabíola V. de Carvalho and Gustavo H. Rodrigues da Silva and Priscila C. Lima Fernandes and Sérgio Q. Brunetto and Celso D. Ramos and Lício A. Velloso and Daniele R. de Araújo and Eneida de Paula},

doi = {10.3390/pharmaceutics13101552},

issn = {1999-4923},

year  = {2021},

date = {2021-10-00},

urldate = {2021-10-00},

journal = {Pharmaceutics},

volume = {13},

number = {10},

publisher = {MDPI AG},

abstract = {<jats:p>Melanoma is the most aggressive skin carcinoma and nanotechnology can bring new options for its pharmacological treatment. Nanostructured lipid carriers (NLC) are ideal drug-delivery carriers for hydrophobic drugs, such as the antineoplastic docetaxel (DTX), and hybrid (NLC-in-hydrogel) systems are suitable for topical application. This work describes a formulation of NLCDTX in xanthan-chitosan hydrogel containing lidocaine (LDC) with anticancer and analgesia effects. The optimized nanoparticles encapsulated 96% DTX and rheological analysis revealed inherent viscoelastic properties of the hydrogel. In vitro assays over murine fibroblasts (NIH/3T3) and melanoma cells (B16-F10), human keratinocytes (HaCaT) and melanoma cells (SK-MEL-103) showed reduction of docetaxel cytotoxicity after encapsulation in NLCDTX and HGel-NLCDTX. Addition of LDC to the hybrid system (HGel-NLCDTX-LDC) increased cell death in tumor and normal cells. In vivo tests on C57BL/6J mice with B16-F10-induced melanoma indicated that LDC, NLCDTX, HGel-NLCDTX-LDC and NLCDTX + HGel-LDC significantly inhibited tumor growth while microPET/SPECT/CT data suggest better prognosis with the hybrid treatment. No adverse effects were observed in cell survival, weight/feed-consumption or serum biochemical markers (ALT, AST, creatinine, urea) of animals treated with NLCDTX or the hybrid system. These results confirm the adjuvant antitumor effect of lidocaine and endorse HGel-NLCDTX-LDC as a promising formulation for the topical treatment of melanoma.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Yoshizane2021,

title = {CT Images of Zebrafish for Preclinical Studies in a Micro PET/SPECT/CT Equipment},

author = {M.K. Yoshizane and S.Q. Brunetto and T.G. Parolari and C.V. Maurer-Morelli and C.D. Ramos},

doi = {10.1088/1748-0221/16/08/p08049},

issn = {1748-0221},

year  = {2021},

date = {2021-08-01},

urldate = {2021-08-01},

journal = {J. Inst.},

volume = {16},

number = {08},

publisher = {IOP Publishing},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33636089,

title = {Simultaneous Imaging of Lung Perfusion and Glucose Metabolism in COVID-19 Pneumonia},

author = {Celso Dario Ramos and Alins P Fernandes and Stephan P M Souza and Mariana Fujiwara and Natalia Tobar and Sergio S J Dertkigil and Maria Emília S Takahashi and Eduardo S L Gonçales and Plinio Trabasso and Denise E Zantut-Wittmann},

doi = {10.1164/rccm.202007-2944IM},

issn = {1535-4970},

year  = {2021},

date = {2021-05-01},

urldate = {2021-05-01},

journal = {Am J Respir Crit Care Med},

volume = {203},

number = {9},

pages = {1186--1187},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Zanetti2021,

title = {Comparison of different fiducial markers to guide SPECT and CT image registration},

author = {T.C. Zanetti and S.Q. Brunetto and E.M. Souza and L.D.S. Sachinelli and C.D. Ramos and D.E. Zantut-Wittmann},

doi = {10.1088/1748-0221/16/05/t05003},

issn = {1748-0221},

year  = {2021},

date = {2021-05-01},

urldate = {2021-05-01},

journal = {J. Inst.},

volume = {16},

number = {05},

publisher = {IOP Publishing},

abstract = {<jats:title>Abstract</jats:title>

               <jats:p>Registration and fusion guided by the fiducial markers of

  SPECT and CT images acquired via distinct equipment is a common

  practice in several nuclear medicine centres. In this study, five

  different fiducial configurations were studied and compared for

  SPECT and CT image acquisitions: iodide-131 (<jats:sup>131</jats:sup>I) within a

  needle cap, <jats:sup>131</jats:sup>I associated with cotton, a lead and a ceramic

  aluminium sphere or mixed with an agarose solution. Fiducials that

  employed agarose mixtures presented the lowest <jats:italic>dpr</jats:italic> values

  (between 0.34 and 0.53 mm) and better homogeneous regions in both

  images to perform registration. In addition, this assembly exhibited

  the lowest global mean <jats:italic>dpr</jats:italic> and standard deviations in

  Gaussian adjustments. In comparison with the other configurations,

  the agarose <jats:italic>dpr</jats:italic> was statistically lower than that of

  cotton, ceramic aluminium and just <jats:sup>131</jats:sup>I for all the six

  landmarks. Despite its similarity with the lead sphere

  configuration, for five of the landmarks, agarose showed no

  artefacts in CT and more homogeneous regions of interest in SPECT

  images. In addition, agarose demonstrated great reproducibility to

  guide point-based registration processes.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deSouza2021,

title = {Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis},

author = {Stephan Pinheiro Macedo de Souza and Natalia Tobar and Fernanda Frasson and Efrain Araujo Perini and Carmino A. de Souza and Marcia T. Delamain and Celso Dario Ramos},

doi = {10.1097/mnm.0000000000001465},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1355--1360},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Ten patients with biopsy-proven-lymphoma underwent 18F-FDG and 68Ga-PSMA-PET/CT (maximum time interval: 6 days). Lymphoma subtypes included Hodgkin’s lymphoma (HL, three patients) and aggressive and indolent non-Hodgkin’s lymphoma (NHL, seven patients). The intensity of PSMA uptake was classified visually as low, intermediate, or high, using blood pool, liver and parotid gland uptake as references. Maximum standardized-uptake value (SUVmax) of each affected site was measured in both sets of images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>FDG detected 59/59 involved sites in 10 patients and PSMA 47/59 sites in nine patients. PSMA uptake was generally low, regardless of the intensity of FDG uptake, but it was classified as intermediate in two patients. The median SUVmax varied from 2.0 (2.0–8.2) to 30.9 for FDG and from 1.7 (1.7–1.7) to 4.4 for PSMA, <jats:italic toggle="yes">P</jats:italic> < 0.0001. The primary lesion of one patient had a marked intralesional mismatch uptake pattern of the tracers, with areas of higher PSMA expression than FDG uptake, and vice-versa. A brain lesion was more easily identified with PSMA than with FDG images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>HL and several NHL subtypes may present PSMA uptake. The intensity of PSMA expression is generally lower than that of FDG uptake and seems to present less variation among the different histological subtypes of lymphomas.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2021b,

title = {Intensity of bone involvement: a quantitative 18F-FDG PET/CT evaluation for monitoring outcome of multiple myeloma},

author = {Maria Emilia Seren Takahashi and Camila Mosci and Gislaine O. Duarte and Fernando V. Pericole and Konradin Metze and Irene G.H. Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001470},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1375--1381},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>The parameter intensity of bone involvement (IBI) was recently proposed to quantitatively assess patients with multiple myeloma using <jats:sup>18</jats:sup>F-fluorodeoxyglucose-PET combined with computed tomography (<jats:sup>18</jats:sup>F-FDG PET/CT) images. Here, we aimed to calculate IBI variation (ΔIBI) between two consecutive PET/CT of the same patient and verified its relationship with a subjective visual analysis of the images and with clinical outcome.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Consecutive whole-body <jats:sup>18</jats:sup>F-FDG PET/CT performed to assess the outcomes of 29 patients diagnosed with multiple myeloma were retrospectively evaluated. ΔIBI was calculated after bone segmentation, using liver standardized uptake value as a threshold to determine metabolically active volumes in the skeleton. For each pair of consecutive PET/CTs, two nuclear medicine physicians classified visually the most recent image as PET-remission, PET-progression or PET-stable when compared to the previous examination.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>The lowest ΔIBI was –1.27 and the highest was 0.29. PET-remission was related to ΔIBI <0 (median = –0.10; –1.27 to +0.03), while PET-progression was related to ΔIBI >0 (median = 0.02; –0.07 to +0.29). ΔIBI around zero was found in images classified as PET-stable (median = 0.00; –0.08 to +0.06). Significant difference in ΔIBI was found between the three groups. Multivariate stepwise analysis showed that IBI value at diagnostic PET/CT, serum calcium and percentage of plasma cells in the bone marrow are independent prognostic factors.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>Delta IBI provides quantitative data for variations of <jats:sup>18</jats:sup>F-FDG uptake in the bone marrow during the follow-up of the patients. In addition, higher IBI values at diagnosis are associated with a higher risk of patient’s death.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2020,

title = {Radium-223 as an Approved Modality for Treatment of Bone Metastases},

author = {Ana Emília Brito and Elba Etchebehere},

doi = {10.1053/j.semnuclmed.2019.11.005},

issn = {0001-2998},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {Seminars in Nuclear Medicine},

volume = {50},

number = {2},

pages = {177--192},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Camacho2019,

title = {Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma},

author = {Mariana R. Camacho and Elba Etchebehere and Natalia Tardelli and Marcia T. Delamain and Aline F.A. Vercosa and Maria E.S. Takahashi and Sergio Q. Brunetto and Irene G.H.L. Metze and Cármino A. Souza and Juliano J. Cerci and Celso D. Ramos},

doi = {10.2967/jnmt.119.231118},

issn = {1535-5675},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {J. Nucl. Med.                Technol.},

volume = {48},

number = {1},

pages = {30--35},

publisher = {Society of Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mosci2020,

title = {99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma},

author = {Camila Mosci and Fernando V. Pericole and Gislaine B. Oliveira and Marcia T. Delamain and Maria E.S. Takahashi and José Barreto C. Carvalheira and Elba C.S.C. Etchebehere and Allan O. Santos and Eliana C. M. Miranda and Mariana C.L. Lima and Barbara J. Amorim and Carmino A. de Souza and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001259},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {10},

pages = {1081--1088},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>

                                 <jats:sup>18</jats:sup>F-fluorodeoxiglucose (<jats:sup>18</jats:sup>F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. <jats:sup>99m</jats:sup>Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Materials and methods</jats:title>

            <jats:p>Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body <jats:sup>18</jats:sup>F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) (<jats:italic toggle="yes">P</jats:italic> = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) (<jats:italic toggle="yes">P</jats:italic> = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively (<jats:italic toggle="yes">P</jats:italic> = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>MIBI SPECT/CT performs similarly to <jats:sup>18</jats:sup>F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a ‘mismatch’ pattern of FDG/MIBI uptake.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2020,

title = {Computed tomography–based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma},

author = {Maria E.S. Takahashi and Camila Mosci and Edna M. Souza and Sérgio Q. Brunetto and Cármino de Souza and Fernando V. Pericole and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001165},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {4},

pages = {377--382},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Quantifications in nuclear medicine are occasionally limited by the lack of standardization for defining volumes of interest (VOIs) on functional images. In the present article, we propose the use of computed tomography (CT)–based skeletal segmentation to determine anatomically the VOI in order to calculate quantitative parameters of fluorine 18 <jats:italic toggle="yes">fluorodeoxyglucose</jats:italic> (<jats:sup>18</jats:sup>F-FDG) PET/CT images from patients with multiple myeloma.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>We evaluated 101 whole-body <jats:sup>18</jats:sup>F-FDG PET/CTs of 58 patients with multiple myeloma. An initial subjective visual analysis of the PET images was used to classify the bone involvement as negative/mild, moderate, or marked. Then, a fully automated CT–based segmentation of the skeleton was performed on PET images. The maximum, mean, and SD of the standardized uptake values (SUV<jats:sub>max</jats:sub>, SUV<jats:sub>mean</jats:sub>, and SD<jats:sub>SUV</jats:sub>) were calculated for bone tissue and compared with the visual analysis.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Forty-five (44.5%), 32 (31.7%), and 24 (23.8%) PET images were, respectively, classified as negative/mild, moderate, or marked bone involvement. All quantitative parameters were significantly related to the visual assessment of bone involvement. This association was stronger for the SUV<jats:sub>mean</jats:sub> [odds ratio (OR): 10.52 (95% confidence interval (CI), 5.68–19.48); <jats:italic toggle="yes">P</jats:italic> < 0.0001] and for the SD<jats:sub>SUV</jats:sub> [OR: 5.58 (95% CI, 3.31–9.42); <jats:italic toggle="yes">P</jats:italic> < 0.001) than for the SUV<jats:sub>max</jats:sub> [OR: 1.01 (95% CI, 1.003–1.022); <jats:italic toggle="yes">P</jats:italic> = 0.003].</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>CT–based skeletal segmentation allows for automated and therefore reproducible calculation of PET quantitative parameters of bone involvement in patients with multiple myeloma. Using this method, the SUV<jats:sub>mean</jats:sub> and its respective SD correlated better with the visual analysis of <jats:sup>18</jats:sup>F-FDG PET images than SUVmax. Its value in staging and evaluating therapy response needs to be evaluated.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Riguetto2020,

title = {Fixed 30 mCi 131I-iodine therapy without recombinant human thyroid-stimulating hormone stimulation as an attractive therapeutic alternative in nontoxic nodular goiter},

author = {Cínthia Minatel Riguetto and Vivian Peraro Miguel and EJ Pavin and Bárbara Juarez Amorim and Celso Darío Ramos and Denise Engelbrecht Zantut-Wittmann},

doi = {10.1097/mnm.0000000000001213},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {8},

pages = {727--732},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Objective</jats:title>

            <jats:p>To analyze outcomes of patients with compressive nontoxic multinodular goiter after 131I-iodine 30 mCi treatment without previous use of recombinant human thyroid-stimulating hormone or methimazole.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>We evaluated fixed-dose radioiodine therapy outcomes in patients with nontoxic multinodular goiter who did not accept thyroidectomy as a therapeutic option. Laboratory thyroid function and thyroid volume estimated by ultrasound were assessed before and one year after radioiodine therapy.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Twenty euthyroid female patients received 30 mCi of 131I-iodine without recombinant human thyroid-stimulating hormone or methimazole pretreatment. Median thyroid volume and Tc-99m sodium pertechnetate thyroid uptake before radioiodine therapy were 68.05 cm<jats:sup>3</jats:sup> (31.3–295.3) and 0.5% (0.1%–1.2%), respectively. One year after radioiodine therapy, thyroid volume decreased to 55.4 cm<jats:sup>3</jats:sup> (19.8–149.9), and merely 4 patients (20%) developed hypothyroidism. Thyroid volume decreased significantly after radioiodine therapy, presenting a variation of −21.1 cm<jats:sup>3</jats:sup> (−161.3 to −0.8) and −30.61% (−73.88 to −1.02), both with <jats:italic toggle="yes">P</jats:italic> < 0.0001. Thyroid volume variation was positively correlated with thyroid uptake in Spearman’s correlation (<jats:italic toggle="yes">r</jats:italic> = 0.4730; <jats:italic toggle="yes">P</jats:italic> = 0.0352). The group satisfied with radioiodine therapy (85%, n = 17) showed a significant reduction in thyroid volume, −25.8 cm<jats:sup>3</jats:sup> (−161.3 to −6.2) and −36.74% (−73.88 to −9.95). The dissatisfied group (15%, n = 3) showed −1.0 cm<jats:sup>3</jats:sup> (−2.0 to −0.8) and −1.67% (−3.38 to −1.02) in thyroid volume, <jats:italic toggle="yes">P</jats:italic> = 0.0081. Patients that complained about dysphagia presented a lower percentage of thyroid volume decrease after radioiodine therapy, −21.97% (−70.12 to −1.02, <jats:italic toggle="yes">P</jats:italic> = 0.0430).</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusions</jats:title>

            <jats:p>A substantial reduction in thyroid volume associated with a low incidence of hypothyroidism and a high satisfaction rate support the use of conventional radioiodine therapy with a fixed dose of 30 mCi. This therapy is an attractive and cheaper therapeutic alternative in selected patients with nontoxic multinodular goiter.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2019,

title = {Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma},

author = {Maria E. S. Takahashi and Camila Mosci and Edna M. Souza and Sérgio Q. Brunetto and Elba Etchebehere and Allan O. Santos and Mariana R. Camacho and Eliana Miranda and Mariana C. L. Lima and Barbara J. Amorim and Carmino de Souza and Fernando V. Pericole and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1038/s41598-019-52740-2},

issn = {2045-2322},

year  = {2019},

date = {2019-12-00},

urldate = {2019-12-00},

journal = {Sci Rep},

volume = {9},

number = {1},

publisher = {Springer Science and Business Media LLC},

abstract = {<jats:title>Abstract</jats:title><jats:p>Many efforts have been made to standardize the interpretation of <jats:sup>18</jats:sup>F-FDG PET/CT in multiple myeloma (MM) with qualitative visual analysis or with quantitative metabolic parameters using various methods for lesion segmentation of PET images. The aim of this study was to propose a quantitative method for bone and bone marrow evaluation of <jats:sup>18</jats:sup>F-FDG PET/CT considering the extent and intensity of bone <jats:sup>18</jats:sup>F-FDG uptake: Intensity of Bone Involvement (IBI). Whole body <jats:sup>18</jats:sup>F-FDG PET/CT of 59 consecutive MM patients were evaluated. Compact bone tissue was segmented in PET images using a global threshold for HU of the registered CT image. A whole skeleton mask was created and the percentage of its volume with <jats:sup>18</jats:sup>F-FDG uptake above hepatic uptake was calculated (Percentage of Bone Involvement - PBI). IBI was defined by multiplying PBI by mean SUV above hepatic uptake. IBI was compared with visual analysis performed by two experienced nuclear medicine physicians. IBI calculation was feasible in all images (range:0.00–1.35). Visual analysis categorized PET exams into three groups (negative/mild, moderate and marked bone involvement), that had different ranges of IBI (multi comparison analysis, p < 0.0001). There was an inverse correlation between the patients’ hemoglobin values and IBI (r = −0.248;p = 0.02). IBI score is an objective measure of bone and bone marrow involvement in MM, allowing the categorization of patients in different degrees of aggressiveness of the bone disease. The next step is to validate IBI in a larger group of patients, before and after treatment and in a multicentre setting.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2018,

title = {Validation of the Semiautomatic Quantification of ^{18}F-Fluoride PET/CT Whole-Body Skeletal Tumor Burden},

author = {Ana E. Brito and Felipe Mourato and Allan Santos and Camila Mosci and Celso Ramos and Elba Etchebehere},

doi = {10.2967/jnmt.118.211474},

issn = {1535-5675},

year  = {2018},

date = {2018-12-00},

urldate = {2018-12-00},

journal = {J. Nucl. Med.                Technol.},

volume = {46},

number = {4},

pages = {378--383},

publisher = {Society of Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Cerci2018,

title = {Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group},

author = {Juliano Júlio Cerci and Mateos Bogoni and Valeria Buccheri and Elba Cristina Sá de Camargo Etchebehere and Talita Maira Bueno da Silveira and Otavio Baiocchi and Carlos de Araujo Cunha Pereira Neto and Marcelo Tatit Sapienza and Jose Flavio Gomes Marin and José Cláudio Meneghetti and Yana Novis and Carmino Antonio de Souza and Carlos Chiattone and Marcia Torresan and Celso Dario Ramos},

doi = {10.1016/j.htct.2018.03.002},

issn = {2531-1379},

year  = {2018},

date = {2018-07-00},

urldate = {2018-07-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {40},

number = {3},

pages = {245--249},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Almeida2018,

title = {Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma},

author = {Ludmila S. Almeida and Maidane C. Araújo and Denise E. Zantut-Wittmann and Lígia V. Assumpção and Thiago F. Souza and Cleide M. Silva and Juliana L. Argenton and Allan O. Santos and Jair Mengatti and Celso D. Ramos and Elba C. Etchebehere},

doi = {10.1097/mnm.0000000000000823},

issn = {0143-3636},

year  = {2018},

date = {2018-00-00},

urldate = {2018-00-00},

volume = {39},

number = {5},

pages = {441--450},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Etchebehere2017,

title = {Therapy assessment of bone metastatic disease in the era of 223radium},

author = {Elba Etchebehere and Ana Emilia Brito and Alireza Rezaee and Werner Langsteger and Mohsen Beheshti},

doi = {10.1007/s00259-017-3734-0},

issn = {1619-7089},

year  = {2017},

date = {2017-08-00},

urldate = {2017-08-00},

journal = {Eur J Nucl Med Mol Imaging},

volume = {44},

number = {S1},

pages = {84--96},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2017,

title = {18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer},

author = {Ana E. Brito and Allan Santos and André Deeke Sasse and Cesar Cabello and Paulo Oliveira and Camila Mosci and Tiago Souza and Barbara Amorim and Mariana Lima and Celso D. Ramos and Elba Etchebehere},

doi = {10.18632/oncotarget.16418},

issn = {1949-2553},

year  = {2017},

date = {2017-05-30},

urldate = {2017-05-30},

journal = {Oncotarget},

volume = {8},

number = {22},

pages = {36001--36011},

publisher = {Impact Journals, LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}